CSCID (CSCID) Stock Price & Analysis
CSCID (CSCID) rose 0.00% to USD 5.5 as of July 25, 2026 at 06:38 UTC, according to Nexqual real-time market data.
CSCID last closed at USD 5.5; the session ranged USD 5.5–5.5 on volume of 100 shares. Market capitalization is $5.84M, with a 52-week range of USD 0.79–9.5 (OQB). Source: Nexqual, July 25, 2026 at 06:38 UTC.
Key Statistics (as of July 25, 2026 at 06:38 UTC)
| Price | USD 5.5 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 5.5 |
| Open | USD 5.5 |
| Day Range | USD 5.5 – 5.5 |
| 52-Week Range | USD 0.79 – 9.5 |
| Volume | 100 shares |
| Market Cap | $5.84M |
| Exchange | OQB |
Technical Analysis (CSCID)
Nexqual's technical model rates CSCID "STRONG BUY" based on 6 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:38 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 67.46 (neutral) |
| vs SMA50 | Above (USD 3.11) |
| MACD | 0.8 (positive) |
Analyst Ratings (CSCID)
Wall Street analysts rate CSCID "None", per Nexqual as of July 25, 2026 at 06:38 UTC.
| Consensus Rating | None |
|---|
Earnings (CSCID)
| Next Earnings Date | 2026-08-13 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -13.92 vs est -11.64 ▼ miss |
| 2023-09-30 | USD -10.2 vs est -7.32 ▼ miss |
| 2023-06-30 | USD -6.24 vs est -10.44 ▲ beat |
| 2023-03-31 | USD -10.56 vs est -12.84 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:38 UTC.
Financials & Fundamentals (CSCID)
| Total Revenue | $8.00M |
|---|---|
| Revenue Growth (YoY) | +36.10% |
| Gross Margin | +37.44% |
| Operating Margin | -38.66% |
| Profit Margin | +50.68% |
| ROE | -61.79% |
| Debt / Equity | 13.21 |
| Current Ratio | 5.57 |
| Total Cash | $5.00M |
| Total Debt | $2.02M |
| Free Cash Flow | $-7.42M |
Source: Nexqual, July 25, 2026 at 06:38 UTC.
Financial Health Score (CSCID)
Nexqual rates CSCID's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:38 UTC.
| Growth | Critical — Revenue -20% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $5M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -62%, ROA -21.3% |
Ownership (CSCID)
| Insider Ownership | +27.53% |
|---|---|
| Institutional Ownership | +403.94% |
| Shares Outstanding | 1.06M |
| Float | 1.06M |
| Short % of Float | +0.26% |
Source: Nexqual, July 25, 2026 at 06:38 UTC.
Leadership (CSCID)
CSCID is led by Peter Harry Puccetti, CEO, President & Chairman, per Nexqual as of July 25, 2026 at 06:38 UTC.
| CEO, President & Chairman | Peter Harry Puccetti |
|---|---|
| Senior VP of Finance & CFO | Giuliano La Fratta |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGMSP | Bio Green Med Solution Inc. | USD 3.5 | ▲ 0% |
| ATOS | Atossa Therapeutics, Inc. | USD 2.3 | ▼ 5.56% |
| TLPH | Talphera, Inc. | USD 1.35 | ▲ 4.65% |
| OGEN | Oragenics Inc. | USD 0.51 | ▼ 3.58% |
| CRIS | Curis, Inc. | USD 4.89 | ▼ 1.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:38 UTC. This page is informational and not investment advice.